Arcus Biosciences, Inc. (RCUS)

NYSE: RCUS · USD

$18.4

+0.27 (+1.5%)· Recorded snapshot

Market cap	2.6B
Revenue (ttm)	117M
Net income (ttm)	-460M
EPS (ttm)	-$3.86
Shares out	143.8M
Volume	1,750,715
Beta	0.94

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 117M
Net income (ttm): -460M
EPS (ttm): -$3.86
Market cap: 2.6B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-90.8

P25 n/aP50 n/aP75 n/a

ROIC-44

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All RCUS indicators

Market & fundamental data

Available fields

197

Groups with data

Currency

USD

Showing 197 of 197 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001724521
Company name	Arcus Biosciences, Inc.
Country	United States
Country code	US
CUSIP number	03969F109
Earnings date	2026-11-04
Earnings time	amc
Employees	601
Employees change	-26
Employees growth	-4.15%
Enterprise value	$2.1B
Exchange	NYSE
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2015
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2018-03-15
Is primary listing	Yes
Is SPAC	No
ISIN number	US03969F1093
Last 10-K release date	2026-02-25
Last earnings date	2026-08-05
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$2.6B
Market cap category	Mid-Cap
Next earnings date	2026-11-04
Options	Yes
Price	$18.41
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	RCUS
U.S. state	California
Website	https://arcusbio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-20.99%
EV/Sales	17.64x
FCF / EV yield	-23.02%
FCF yield	-18.26%
Forward EV/Sales	78.78x
Forward P/S	99.28x
P/B ratio	4.97x
P/S ratio	22.23x
Price / tangible book value	5.6x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Operating margin	-415.38%
Pretax margin	-393.16%
Profit per employee	$-765,391
Revenue per employee	$194,676
ROA	-30.39%
ROA (5Y)	-12.96%
ROCE	-66.94%
ROE	-90.82%
ROE (5Y)	-41.13%
ROIC	-43.99%
SBC / revenue	53.85%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
Net income growth years	0
Revenue growth	-55.34%
Revenue growth (Q)	-74.38%
Revenue growth (QoQ)	141.18%
Revenue growth 3Y	-1.11%
Revenue growth 5Y	4.71%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-1M
Depreciation and amortization	$10M
EBIT	$-486M
EBITDA	$-476M
EPS	$-3.86
FCF per share	$-3.30
Financing cash flow	$313M
Free cash flow	$-475M
Free cash flow minus SBC	$-538M
Gross profit	$-380M
Investing cash flow	$63M
Net cash flow	$-98M
Net income	$-460M
Operating cash flow minus SBC	$-537M
Operating income	$-486M
Revenue	$117M
Stock-based compensation	$63M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-0.44
Book value per share	$3.65
Debt / equity	0.51
Interest coverage	-44.18
Long-term assets	$168M
Long-term liabilities	$262M
Net cash (debt)	$537M
Net cash / market cap	20.65%
Net cash growth	-32.62%
Net debt / equity	-1.16
Piotroski F-Score	0
Property, plant and equipment	$36M
Shareholders' equity	$464M
Tangible book value	$464M
Tangible book value per share	$3.65
Total assets	$924M
Total cash	$702M
Total debt	$238M
Total liabilities	$460M
WACC	8.93%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.12
Current assets	$756M
Current liabilities	$198M
Current ratio	3.82
Net working capital	$-131M
Quick ratio	3.75
Working capital	$558M
Working capital turnover	0.18

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-22.85%
Dividend yield	0%
Shareholder yield	-22.85%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$25.75
1D price change	1.49%
1M price change	-27.59%
1M total return	-27.59%
1W price change	-23.87%
1W total return	-23.87%
1Y price change	-2.8%
1Y return CAGR	-2.8%
1Y total return	-2.8%
20-day SMA	$22.13
200-day SMA	$24.72
3M price change	-35.06%
3M total return	-35.06%
3Y price change	26.17%
3Y return CAGR	8.06%
3Y total return	26.17%
50-day SMA	$25.43
50-day SMA vs 200-day SMA	50over200
52-week high	$31.74
52-week high date	2026-06-30
52-week low	$17.43
52-week low date	2026-10-22
5Y price change	-45.36%
5Y return CAGR	-11.39%
5Y total return	-45.36%
6M price change	-27.54%
6M total return	-27.54%
All-time high	$49.10
All-time high date	2021-11-22
All-time low	$6.30
All-time low date	2019-08-05
Average true range (ATR)	$1.50
Average volume	2.5M
Beta (1Y)	1.06
Beta (2Y)	1.67
Beta (5Y)	0.94
Change from 52-week high	-41.99%
Change from 52-week low	5.62%
Change from all-time high	-63.18%
Change from all-time low	186.98%
Change from open	2.56%
Day's gap	-1.05%
Dollar volume	$32.2M
High price	$18.49
Low price	$17.77
Monthly RSI	46.43
Open price	$17.95
Position in 52-week range	88.89%
Premarket change	-0.14%
Premarket close	$18.14
Premarket price	$18.11
Premarket volume	241
Previous close	$18.14
Price vs 150-day SMA	-29.8%
Price vs 20-day SMA	-18.31%
Price vs 200-day SMA	-26.85%
Price vs 50-day SMA	-28.91%
Relative volume	0.71
RSI	28.03
Sharpe ratio	0.2
Sharpe ratio (3Y)	0.31
Sharpe ratio (5Y)	0.09
Sortino ratio	0.37
Sortino ratio (3Y)	0.54
Sortino ratio (5Y)	0.22
Volume	1.8M
Weekly RSI	32.93
YTD price change	-24.13%
YTD total return	-24.13%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	104.8M
Float percentage	72.91%
Shares change (QoQ)	0.56%
Shares change (YoY)	22.85%
Shares held by insiders	3.19%
Shares held by institutions	64.71%
Shares outstanding	143.8M
Short % of float	12.51%
Short % of shares	9.12%
Short ratio	7.7 days

Deeper analysis on RCUS

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this RCUS report

Is a complete RCUS research report available?

No complete published report is available for Arcus Biosciences, Inc. (RCUS) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Arcus Biosciences, Inc. (RCUS)

Price

Financial snapshot

Fair-value bridge

Latest news · RCUS

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All RCUS indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on RCUS

Frequently asked questions